SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Chesi, M. Articles by Kuehl, W. M. Search for Related Content PubMed PubMed Citation Articles by Chesi, M. Articles by Kuehl, W. M. Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Frequent Dysregulation of the c-maf Proto-Oncogene at 16q23 by Translocation to an Ig Locus in Multiple Myeloma Marta Chesi, P. Leif Bergsagel, Oluwatoyin O. Shonukan, Maria Luisa Martelli, Leslie A. Brents, Theresa Chen, Evelin Schröck, Thomas Ried, and W. Michael Kuehl From the Genetics Department, Medicine Branch, National Cancer Institute, Bethesda, MD; the Department of Medicine, Division of Hematology and Oncology, Cornell University Medical College, New York, NY; and the Genome Technology Branch, National Institutes of Health-National Center for Human Genome Research, Bethesda, MD. Dysregulation of oncogenes by translocation to an IgH (14q32) or IgL (, 2p11 or , 22q11) locus is a frequent event in the pathogenesis of B-cell tumors. Translocations involving an IgH locus and a diverse but nonrandom array of chromosomal loci occur in most multiple myeloma (MM) tumors even though the translocations often are not detected by conventional cytogenetic analysis. In a continuing analysis of translocations in 21 MM lines, we show that the novel, karyotypically silent t(14;16)(q32.3;q23) translocation is present in 5 MM lines, with cloned breakpoints from 4 lines dispersed over an approximately 500-kb region centromeric to the c-maf proto-oncogene at 16q23. Another line has a t(16;22)(q23;q11), with the breakpoint telomeric to c-maf, so that the translocation breakpoints in these 6 lines bracket c-maf. Only these 6 lines overexpress c-maf mRNA. As predicted for dysregulation of c-maf by translocation, there is selective expression of one c-maf allele in 2 informative lines with translocations. This is the first human tumor in which the basic zipper c-maf transcription factor is shown to function as an oncogene. Blood, Vol. 91 No. 12 (June 15), 1998: pp. 4457-4463 © 1998 by The American Society of Hematology. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: Y. Natkunam, S. Tedoldi, J. C. Paterson, S. Zhao, M. Rodriguez-Justo, A. H. Beck, R. Siebert, D. Y. Mason, and T. Marafioti Characterization of c-Maf Transcription Factor in Normal and Neoplastic Hematolymphoid Tissue and Its Relevance in Plasma Cell Neoplasia Am J Clin Pathol, September 1, 2009; 132(3): 361 - 371. [Abstract] [Full Text] [PDF] P. Broet, S. Camilleri-Broet, S. Zhang, M. Alifano, D. Bangarusamy, M. Battistella, Y. Wu, M. Tuefferd, J.-F. Regnard, E. Lim, et al. Prediction of Clinical Outcome in Multiple Lung Cancer Cohorts by Integrative Genomics: Implications for Chemotherapy Selection Cancer Res., February 1, 2009; 69(3): 1055 - 1062. [Abstract] [Full Text] [PDF] P. Frost, Y. Shi, B. Hoang, J. Gera, and A. Lichtenstein Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin Mol. Cancer Ther., January 1, 2009; 8(1): 83 - 93. [Abstract] [Full Text] [PDF] J Yeung and H Chang Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma J. Clin. Pathol., July 1, 2008; 61(7): 832 - 836. [Abstract] [Full Text] [PDF] A. Dib, A. Gabrea, O. K. Glebov, P. L. Bergsagel, and W. M. Kuehl Characterization of MYC Translocations in Multiple Myeloma Cell Lines J Natl Cancer Inst Monographs, July 1, 2008; 2008(39): 25 - 31. [Abstract] [Full Text] [PDF] J. Lauring, A. M. Abukhdeir, H. Konishi, J. P. Garay, J. P. Gustin, Q. Wang, R. J. Arceci, W. Matsui, and B. H. Park The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity Blood, January 15, 2008; 111(2): 856 - 864. [Abstract] [Full Text] [PDF] M. W. Jenner, P. E. Leone, B. A. Walker, F. M. Ross, D. C. Johnson, D. Gonzalez, L. Chiecchio, E. Dachs Cabanas, G. Paolo Dagrada, M. Nightingale, et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma Blood, November 1, 2007; 110(9): 3291 - 3300. [Abstract] [Full Text] [PDF] D. Gonzalez, M. van der Burg, R. Garcia-Sanz, J. A. Fenton, A. W. Langerak, M. Gonzalez, J. J. M. van Dongen, J. F. San Miguel, and G. J. Morgan Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma Blood, November 1, 2007; 110(9): 3112 - 3121. [Abstract] [Full Text] [PDF] C. Atayar, A. van den Berg, T. Blokzijl, M. Boot, R. D Gascoyne, L. Visser, and S. Poppema Hodgkin's lymphoma associated T-cells exhibit a transcription factor profile consistent with distinct lymphoid compartments J. Clin. Pathol., October 1, 2007; 60(10): 1092 - 1097. [Abstract] [Full Text] [PDF] W. W.-L. Wong, J. W. Clendening, A. Martirosyan, P. C. Boutros, C. Bros, F. Khosravi, I. Jurisica, A. K. Stewart, P. L. Bergsagel, and L. Z. Penn Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma Mol. Cancer Ther., June 1, 2007; 6(6): 1886 - 1897. [Abstract] [Full Text] [PDF] H. Avet-Loiseau, M. Attal, P. Moreau, C. Charbonnel, F. Garban, C. Hulin, S. Leyvraz, M. Michallet, I. Yakoub-Agha, L. Garderet, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome Blood, April 15, 2007; 109(8): 3489 - 3495. [Abstract] [Full Text] [PDF] R. Fonseca and A. K. Stewart Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach Mol. Cancer Ther., March 1, 2007; 6(3): 802 - 810. [Abstract] [Full Text] [PDF] J. R. Cook, M. Hartke, J. Pettay, and R. R. Tubbs Fluorescence in Situ Hybridization Analysis of Immunoglobulin Heavy Chain Translocations in Plasma Cell Myeloma Using Intact Paraffin Sections and Simultaneous CD138 Immunofluorescence J. Mol. Diagn., September 1, 2006; 8(4): 459 - 465. [Abstract] [Full Text] [PDF] W. Massrieh, A. Derjuga, F. Doualla-Bell, C.-Y. Ku, B. M. Sanborn, and V. Blank Regulation of the MAFF Transcription Factor by Proinflammatory Cytokines in Myometrial Cells Biol Reprod, April 1, 2006; 74(4): 699 - 705. [Abstract] [Full Text] [PDF] G. Bisping, M. Kropff, D. Wenning, B. Dreyer, S. Bessonov, F. Hilberg, G. J. Roth, G. Munzert, M. Stefanic, M. Stelljes, et al. Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups Blood, March 1, 2006; 107(5): 2079 - 2089. [Abstract] [Full Text] [PDF] N. Morito, K. Yoh, Y. Fujioka, T. Nakano, H. Shimohata, Y. Hashimoto, A. Yamada, A. Maeda, F. Matsuno, H. Hata, et al. Overexpression of c-Maf Contributes to T-Cell Lymphoma in Both Mice and Human Cancer Res., January 15, 2006; 66(2): 812 - 819. [Abstract] [Full Text] [PDF] L. Agnelli, S. Bicciato, M. Mattioli, S. Fabris, D. Intini, D. Verdelli, L. Baldini, F. Morabito, V. Callea, L. Lombardi, et al. Molecular Classification of Multiple Myeloma: A Distinct Transcriptional Profile Characterizes Patients Expressing CCND1 and Negative for 14q32 Translocations J. Clin. Oncol., October 10, 2005; 23(29): 7296 - 7306. [Abstract] [Full Text] [PDF] W. Jaksic, S. Trudel, H. Chang, Y. Trieu, X. Qi, J. Mikhael, D. Reece, C. Chen, and A. K. Stewart Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance J. Clin. Oncol., October 1, 2005; 23(28): 7069 - 7073. [Abstract] [Full Text] [PDF] P. L. Bergsagel and W. M. Kuehl Molecular Pathogenesis and a Consequent Classification of Multiple Myeloma J. Clin. Oncol., September 10, 2005; 23(26): 6333 - 6338. [Abstract] [Full Text] [PDF] A. K. Stewart and R. Fonseca Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling J. Clin. Oncol., September 10, 2005; 23(26): 6339 - 6344. [Abstract] [Full Text] [PDF] J. Chen, I. R. Williams, B. H. Lee, N. Duclos, B. J. P. Huntly, D. J. Donoghue, and D. G. Gilliland Constitutively activated FGFR3 mutants signal through PLC{gamma}-dependent and -independent pathways for hematopoietic transformation Blood, July 1, 2005; 106(1): 328 - 337. [Abstract] [Full Text] [PDF] M. Finnis, S. Dayan, L. Hobson, G. Chenevix-Trench, K. Friend, K. Ried, D. Venter, E. Woollatt, E. Baker, and R. I. Richards Common chromosomal fragile site FRA16D mutation in cancer cells Hum. Mol. Genet., May 15, 2005; 14(10): 1341 - 1349. [Abstract] [Full Text] [PDF] K. Turcotte, S. Gauthier, A. Tuite, A. Mullick, D. Malo, and P. Gros A mutation in the Icsbp1 gene causes susceptibility to infection and a chronic myeloid leukemia-like syndrome in BXH-2 mice J. Exp. Med., March 21, 2005; 201(6): 881 - 890. [Abstract] [Full Text] [PDF] S. Cao, J. Liu, L. Song, and X. Ma The Protooncogene c-Maf Is an Essential Transcription Factor for IL-10 Gene Expression in Macrophages J. Immunol., March 15, 2005; 174(6): 3484 - 3492. [Abstract] [Full Text] [PDF] B. Chenais, A. Derjuga, W. Massrieh, K. Red-Horse, V. Bellingard, S. J. Fisher, and V. Blank Functional and Placental Expression Analysis of the Human NRF3 Transcription Factor Mol. Endocrinol., January 1, 2005; 19(1): 125 - 137. [Abstract] [Full Text] [PDF] C. Atayar, S. Poppema, T. Blokzijl, G. Harms, M. Boot, and A. van den Berg Expression of the T-Cell Transcription Factors, GATA-3 and T-bet, in the Neoplastic Cells of Hodgkin Lymphomas Am. J. Pathol., January 1, 2005; 166(1): 127 - 134. [Abstract] [Full Text] [PDF] F. Magrangeas, M.-L. Cormier, G. Descamps, N. Gouy, L. Lode, M.-P. Mellerin, J.-L. Harousseau, R. Bataille, S. Minvielle, and H. Avet-Loiseau Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level Blood, May 15, 2004; 103(10): 3869 - 3875. [Abstract] [Full Text] [PDF] T. Stromberg, A. Dimberg, A. Hammarberg, K. Carlson, A. Osterborg, K. Nilsson, and H. Jernberg-Wiklund Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone Blood, April 15, 2004; 103(8): 3138 - 3147. [Abstract] [Full Text] [PDF] R. Fonseca, B. Barlogie, R. Bataille, C. Bastard, P. L. Bergsagel, M. Chesi, F. E. Davies, J. Drach, P. R. Greipp, I. R. Kirsch, et al. Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report Cancer Res., February 15, 2004; 64(4): 1546 - 1558. [Abstract] [Full Text] [PDF] M. Cuendet, K. Christov, D. D. Lantvit, Y. Deng, S. Hedayat, L. Helson, J. D. McChesney, and J. M. Pezzuto Multiple Myeloma Regression Mediated by Bruceantin Clin. Cancer Res., February 1, 2004; 10(3): 1170 - 1179. [Abstract] [Full Text] [PDF] A. Valanciute, S. le Gouvello, B. Solhonne, A. Pawlak, P. Grimbert, L. Lyonnet, S. Hue, P. Lang, P. Remy, R. Salomon, et al. NF-{kappa}B p65 Antagonizes IL-4 Induction by c-maf in Minimal Change Nephrotic Syndrome J. Immunol., January 1, 2004; 172(1): 688 - 698. [Abstract] [Full Text] [PDF] K. Brocke-Heidrich, A. K. Kretzschmar, G. Pfeifer, C. Henze, D. Loffler, D. Koczan, H.-J. Thiesen, R. Burger, M. Gramatzki, and F. Horn Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation Blood, January 1, 2004; 103(1): 242 - 251. [Abstract] [Full Text] [PDF] S. Soverini, M. Cavo, C. Cellini, C. Terragna, E. Zamagni, D. Ruggeri, N. Testoni, P. Tosi, A. de Vivo, M. Amabile, et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation Blood, September 1, 2003; 102(5): 1588 - 1594. [Abstract] [Full Text] [PDF] R. Fonseca, E. Blood, M. Rue, D. Harrington, M. M. Oken, R. A. Kyle, G. W. Dewald, B. Van Ness, S. A. Van Wier, K. J. Henderson, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma Blood, June 1, 2003; 101(11): 4569 - 4575. [Abstract] [Full Text] [PDF] R V Jamieson, F Munier, A Balmer, N Farrar, R Perveen, and G C M Black Pulverulent cataract with variably associated microcornea and iris coloboma in a MAF mutation family Br J Ophthalmol, April 1, 2003; 87(4): 411 - 412. [Abstract] [Full Text] [PDF] J. J. Keats, T. Reiman, C. A. Maxwell, B. J. Taylor, L. M. Larratt, M. J. Mant, A. R. Belch, and L. M. Pilarski In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression Blood, February 15, 2003; 101(4): 1520 - 1529. [Abstract] [Full Text] [PDF] S. Cao, J. Liu, M. Chesi, P. L. Bergsagel, I-C. Ho, R. P. Donnelly, and X. Ma Differential Regulation of IL-12 and IL-10 Gene Expression in Macrophages by the Basic Leucine Zipper Transcription Factor c-Maf Fibrosarcoma J. Immunol., November 15, 2002; 169(10): 5715 - 5725. [Abstract] [Full Text] [PDF] P. S. Nelson, N. Clegg, H. Arnold, C. Ferguson, M. Bonham, J. White, L. Hood, and B. Lin The program of androgen-responsive genes in neoplastic prostate epithelium PNAS, September 3, 2002; 99(18): 11890 - 11895. [Abstract] [Full Text] [PDF] D. J. Cousins, T. H. Lee, and D. Z. Staynov Cytokine Coexpression During Human Th1/Th2 Cell Differentiation: Direct Evidence for Coordinated Expression of Th2 Cytokines J. Immunol., September 1, 2002; 169(5): 2498 - 2506. [Abstract] [Full Text] [PDF] J. O. Claudio, E. Masih-Khan, H. Tang, J. Goncalves, M. Voralia, Z. H. Li, V. Nadeem, E. Cukerman, O. Francisco-Pabalan, C. C. Liew, et al. A molecular compendium of genes expressed in multiple myeloma Blood, August 28, 2002; 100(6): 2175 - 2186. [Abstract] [Full Text] [PDF] R. Fonseca, R. J. Bailey, G. J. Ahmann, S. V. Rajkumar, J. D. Hoyer, J. A. Lust, R. A. Kyle, M. A. Gertz, P. R. Greipp, and G. W. Dewald Genomic abnormalities in monoclonal gammopathy of undetermined significance Blood, July 30, 2002; 100(4): 1417 - 1424. [Abstract] [Full Text] [PDF] R. Fonseca, E. A. Blood, M. M. Oken, R. A. Kyle, G. W. Dewald, R. J. Bailey, S. A. Van Wier, K. J. Henderson, J. D. Hoyer, D. Harrington, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients Blood, May 15, 2002; 99(10): 3735 - 3741. [Abstract] [Full Text] [PDF] H. Avet-Loiseau, T. Facon, B. Grosbois, F. Magrangeas, M.-J. Rapp, J.-L. Harousseau, S. Minvielle, and R. Bataille Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation Blood, March 15, 2002; 99(6): 2185 - 2191. [Abstract] [Full Text] [PDF] R. V. Jamieson, R. Perveen, B. Kerr, M. Carette, J. Yardley, E. Heon, M. G. Wirth, V. van Heyningen, D. Donnai, F. Munier, et al. Domain disruption and mutation of the bZIP transcription factor, MAF,associated with cataract, ocular anterior segment dysgenesis and coloboma Hum. Mol. Genet., January 1, 2002; 11(1): 33 - 42. [Abstract] [Full Text] [PDF] H. Avet-Loiseau, F. Gerson, F. Magrangeas, S. Minvielle, J.-L. Harousseau, and R. Bataille Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors Blood, November 15, 2001; 98(10): 3082 - 3086. [Abstract] [Full Text] [PDF] S. R. Hayman, R. J. Bailey, S. M. Jalal, G. J. Ahmann, A. Dispenzieri, M. A. Gertz, P. R. Greipp, R. A. Kyle, M. Q. Lacy, S. V. Rajkumar, et al. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis Blood, October 1, 2001; 98(7): 2266 - 2268. [Abstract] [Full Text] [PDF] N. Kalakonda, D. G. Rothwell, J. H. Scarffe, and J. D. Norton Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation Blood, September 1, 2001; 98(5): 1555 - 1560. [Abstract] [Full Text] [PDF] J. Shaughnessy Jr, A. Gabrea, Y. Qi, L. Brents, F. Zhan, E. Tian, J. Sawyer, B. Barlogie, P. L. Bergsagel, and M. Kuehl Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma Blood, July 1, 2001; 98(1): 217 - 223. [Abstract] [Full Text] [PDF] V. Perfetti, A. M. L. Coluccia, D. Intini, U. Malgeri, M. C. Vignarelli, S. Casarini, G. Merlini, and A. Neri Translocation t(4;14)(p16.3;q32) Is a Recurrent Genetic Lesion in Primary Amyloidosis Am. J. Pathol., May 1, 2001; 158(5): 1599 - 1603. [Abstract] [Full Text] [PDF] Z. Li, Y. X. Zhu, E. E. Plowright, P. L. Bergsagel, M. Chesi, B. Patterson, T. S. Hawley, R. G. Hawley, and A. K. Stewart The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells Blood, April 15, 2001; 97(8): 2413 - 2419. [Abstract] [Full Text] [PDF] A. Skapenko, P. E. Lipsky, H.-G. Kraetsch, J. R. Kalden, and H. Schulze-Koops Antigen-Independent Th2 Cell Differentiation by Stimulation of CD28: Regulation Via IL-4 Gene Expression and Mitogen-Activated Protein Kinase Activation J. Immunol., April 1, 2001; 166(7): 4283 - 4292. [Abstract] [Full Text] [PDF] M. Sakai, M. S. Serria, H. Ikeda, K. Yoshida, J. Imaki, and S. Nishi Regulation of c-maf gene expression by Pax6 in cultured cells Nucleic Acids Res., March 1, 2001; 29(5): 1228 - 1237. [Abstract] [Full Text] [PDF] M. Chesi, L. A. Brents, S. A. Ely, C. Bais, D. F. Robbiani, E. A. Mesri, W. M. Kuehl, and P. L. Bergsagel Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma Blood, February 1, 2001; 97(3): 729 - 736. [Abstract] [Full Text] [PDF] H. Avet-Loiseau, A. Daviet, C. Brigaudeau, E. Callet-Bauchu, C. Terre, M. Lafage-Pochitaloff, F. Desangles, S. Ramond, P. Talmant, and R. Bataille Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique Blood, February 1, 2001; 97(3): 822 - 825. [Abstract] [Full Text] [PDF] P. J. Ho, R. D. Brown, G. J. Pelka, A. Basten, J. Gibson, and D. E. Joshua Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival Blood, January 15, 2001; 97(2): 490 - 495. [Abstract] [Full Text] [PDF] W. S. Dalton, P. L. Bergsagel, W. M. Kuehl, K. C. Anderson, and J. L. Harousseau Multiple Myeloma Hematology, January 1, 2001; 2001(1): 157 - 177. [Abstract] [Full Text] [PDF] J. Shaughnessy Jr, E. Tian, J. Sawyer, K. Bumm, R. Landes, A. Badros, C. Morris, G. Tricot, J. Epstein, and B. Barlogie High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH Blood, August 15, 2000; 96(4): 1505 - 1511. [Abstract] [Full Text] [PDF] U. Malgeri, L. Baldini, V. Perfetti, S. Fabris, M. C. Vignarelli, G. Colombo, V. Lotti, S. Compasso, S. Bogni, L. Lombardi, et al. Detection of t(4;14)(p16.3;q32) Chromosomal Translocation in Multiple Myeloma by Reverse Transcription-Polymerase Chain Reaction Analysis of IGH-MMSET Fusion Transcripts Cancer Res., August 1, 2000; 60(15): 4058 - 4061. [Abstract] [Full Text] T. G. Willis and M. J. S. Dyer The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies Blood, August 1, 2000; 96(3): 808 - 822. [Full Text] [PDF] T. Szczepanski, M. B. van 't Veer, I. L. M. Wolvers-Tettero, A. W. Langerak, and J. J. M. van Dongen Molecular features responsible for the absence of immunoglobulin heavy chain protein synthesis in an IgH- subgroup of multiple myeloma Blood, August 1, 2000; 96(3): 1087 - 1093. [Abstract] [Full Text] [PDF] K. Ried, M. Finnis, L. Hobson, M. Mangelsdorf, S. Dayan, J. K. Nancarrow, E. Woollatt, G. Kremmidiotis, A. Gardner, D. Venter, et al. Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells Hum. Mol. Genet., July 1, 2000; 9(11): 1651 - 1663. [Abstract] [Full Text] [PDF] G. Pruneri, S. Fabris, L. Baldini, N. Carboni, S. Zagano, M. A. Colombi, G. Ciceri, L. Lombardi, M. Rocchi, R. Buffa, et al. Immunohistochemical Analysis of Cyclin D1 Shows Deregulated Expression in Multiple Myeloma with the t(11;14) Am. J. Pathol., May 1, 2000; 156(5): 1505 - 1513. [Abstract] [Full Text] [PDF] J. W. G. Janssen, J.-W. Vaandrager, T. Heuser, A. Jauch, P. M. Kluin, E. Geelen, P. L. Bergsagel, W. M. Kuehl, H. G. Drexler, T. Otsuki, et al. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32) Blood, April 15, 2000; 95(8): 2691 - 2698. [Abstract] [Full Text] [PDF] A. K. Bednarek, K. J. Laflin, R. L. Daniel, Q. Liao, K. A. Hawkins, and C. M. Aldaz WWOX, a Novel WW Domain-containing Protein Mapping to Human Chromosome 16q23.3-24.1, a Region Frequently Affected in Breast Cancer Cancer Res., April 1, 2000; 60(8): 2140 - 2145. [Abstract] [Full Text] M. Mangelsdorf, K. Ried, E. Woollatt, S. Dayan, H. Eyre, M. Finnis, L. Hobson, J. Nancarrow, D. Venter, E. Baker, et al. Chromosomal Fragile Site FRA16D and DNA Instability in Cancer Cancer Res., March 1, 2000; 60(6): 1683 - 1689. [Abstract] [Full Text] A. J. W. Paige, K. J. Taylor, A. Stewart, J. G. Sgouros, H. Gabra, G. C. Sellar, J. F. Smyth, D. J. Porteous, and J. E. V. Watson A 700-kb Physical Map of a Region of 16q23.2 Homozygously Deleted in Multiple Cancers and Spanning the Common Fragile Site FRA16D Cancer Res., March 1, 2000; 60(6): 1690 - 1697. [Abstract] [Full Text] E. E. Plowright, Z. Li, P. L. Bergsagel, M. Chesi, D. L. Barber, D. R. Branch, R. G. Hawley, and A. K. Stewart Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis Blood, February 1, 2000; 95(3): 992 - 998. [Abstract] [Full Text] [PDF] Y. Shou, M. L. Martelli, A. Gabrea, Y. Qi, L. A. Brents, A. Roschke, G. Dewald, I. R. Kirsch, P. L. Bergsagel, and W. M. Kuehl Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma PNAS, January 4, 2000; 97(1): 228 - 233. [Abstract] [Full Text] [PDF] M. Li, X. Huang, Z. Zhu, and E. Gorelik Sequence and Insertion Sites of Murine Melanoma-Associated Retrovirus J. Virol., November 1, 1999; 73(11): 9178 - 9186. [Abstract] [Full Text] [PDF] P. Finelli, S. Fabris, S. Zagano, L. Baldini, D. Intini, L. Nobili, L. Lombardi, A. T. Maiolo, and A. Neri Detection of t(4;14)(p16.3;q32) Chromosomal Translocation in Multiple Myeloma by Double-Color Fluorescent In Situ Hybridization Blood, July 15, 1999; 94(2): 724 - 732. [Abstract] [Full Text] [PDF] M. Chesi, E. Nardini, R. S.C. Lim, K. D. Smith, W. M. Kuehl, and P. L. Bergsagel The t(4;14) Translocation in Myeloma Dysregulates Both FGFR3 and a Novel Gene, MMSET, Resulting in IgH/MMSET Hybrid Transcripts Blood, November 1, 1998; 92(9): 3025 - 3034. [Abstract] [Full Text] [PDF] T. K. Hale, C. Myers, R. Maitra, T. Kolzau, M. Nishizawa, and A. W. Braithwaite Maf Transcriptionally Activates the Mouse p53 Promoter and Causes a p53-dependent Cell Death J. Biol. Chem., June 9, 2000; 275(24): 17991 - 17999. [Abstract] [Full Text] [PDF] K. Kataoka, K. Yoshitomo-Nakagawa, S. Shioda, and M. Nishizawa A Set of Hox Proteins Interact with the Maf Oncoprotein to Inhibit Its DNA Binding, Transactivation, and Transforming Activities J. Biol. Chem., January 5, 2001; 276(1): 819 - 826. [Abstract] [Full Text] [PDF] K. Kataoka, S. Shioda, K. Yoshitomo-Nakagawa, H. Handa, and M. Nishizawa Maf and Jun Nuclear Oncoproteins Share Downstream Target Genes for Inducing Cell Transformation J. Biol. Chem., September 21, 2001; 276(39): 36849 - 36856. [Abstract] [Full Text] [PDF]

	Copyright © 1998 by American Society of Hematology         Online ISSN: 1528-0020